De Novo Announces Drug Discovery Collaboration with Genzyme
News Jan 19, 2006
De Novo Pharmaceuticals Ltd. has announced that it has entered into a drug discovery collaboration agreement with Genzyme whereby De Novo will apply its molecular structure generating technology to focus on a disease target of interest to Genzyme.
"We are very pleased to be working with Genzyme," said Philip Dean, Ph.D., CSO at De Novo.
"Using SkelGen, we will be designing for Genzyme new chemical classes of inhibitors to an important biological target implicated in multiple diseases," he added.
"This collaboration will enhance Genzyme's ability to discover cutting-edge therapeutics using a structure-based design approach," said Thomas Jozefiak, Ph.D., Senior Scientific Director, Chemical Research at Genzyme.
The core platform at De Novo is a suite of structure generating programs called SkelGen, which has been evaluated and co-developed by Roche.
With regard to the De Novo Technology, Philip added, "The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ."
"Ninety-per cent of the structures produced by SkelGen are novel and chemically tractable. This represents a significant advancement in the field of De Novo design and potential paradigm shift for drug discovery."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE